Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.93T
24h Vol:
$8.65B
Dominance:
MSFT:4.81%
Stocklytics Platform
Instrument logo  LLY
Eli Lilly & Co
LLY
74 / 100
High Growth
S&P500
$733.51arrow_drop_up1.19%$8.64

Performance History

Stocklytics logo
Key Stats
Open$723.47
Prev. Close$724.87
EPS5.78
Dividend$4.69
Next Earnings DateJun 7, 2024
Dividend Yield %0.71%
Market Cap$695.32B
PE Ratio126.90
LOWHIGH
Day Range721.00
737.45
52 Week Range370.67
800.78
Ratios
P/B Ratio66.34
Revenue$34.12B
Operating M. %34.14%
Earnings$5.24B
Earnings Growth %-16.08%
EBITDA Margin %36.09%
ROE %48.44%
EPS5.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

74vs 55. Market Avg.

All Score 74 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

LLYMARKET
Value2640
Quality6940
Ownership4317
Growth7543
Dividends3938
check_circle

Eli Lilly & Co's Price growth average in the last 3 years of 60.43% is great compared to market average of 6.11%. This indicates LLY could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$495.35
24H (%)arrow_drop_up0.30%
24H ($)$1.49
MARKET CAP$454.39B
PRICE$146.14
24H (%)arrow_drop_down0.46%
24H ($)-$0.68
MARKET CAP$359.34B
PRICE$131.20
24H (%)arrow_drop_up0.36%
24H ($)$0.48
MARKET CAP$321.39B
PRICE$159.62
24H (%)arrow_drop_down4.58%
24H ($)-$7.67
MARKET CAP$296.75B

About Eli Lilly & Co (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. David A. Ricks
Headquarters
Indianapolis
Employees
39000
Exchange
NYSE
add Eli Lilly & Co to watchlist

Keep an eye on Eli Lilly & Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Eli Lilly & Co's (LLY) price per share?

The current price per share for Eli Lilly & Co (LLY) is $733.51. The stock has seen a price change of $8.64 recently, indicating a 1.19% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Eli Lilly & Co (LLY)?

For Eli Lilly & Co (LLY), the 52-week high is $800.78, which is 9.17% from the current price. The 52-week low is $370.68, the current price is 97.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Eli Lilly & Co (LLY) a growth stock?

Eli Lilly & Co (LLY) has shown an average price growth of 59.17% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eli Lilly & Co as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Eli Lilly & Co (LLY) stock price performance year to date (YTD)?

As of the latest data, Eli Lilly & Co (LLY) has a year-to-date price change of 23.86%. Over the past month, the stock has experienced a price change of -5.34%. Over the last three months, the change has been 14.75%. Over the past six months, the figure is 29.12%. Looking at a longer horizon, the five-year price change stands at 511.92%.

help
Is Eli Lilly & Co (LLY) a profitable company?

Eli Lilly & Co (LLY) has a net income of $5.24B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 80.73% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 34.14% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $34.12B, with a revenue growth rate of 19.56%, providing insight into the company's sales performance and growth. The gross profit is $27.55B. Operating income is noted at $10.33B. Furthermore, the EBITDA is $12.46B.

help
What is the market capitalization of Eli Lilly & Co (LLY)?

Eli Lilly & Co (LLY) has a market capitalization of $695.32B. The average daily trading volume is 2.44M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.